Anzeige
Mehr »
Login
Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
19.06.24
09:08 Uhr
0,141 Euro
-0,017
-10,76 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1740,19012:53

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAngle PLC Announces Posting of 2023 Annual Report & Notice of the AGM155GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use...
► Artikel lesen
11.06.Angle PLC Announces Parsortix and Assays being Showcased at EACR 2024114PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCHANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis...
► Artikel lesen
06.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 06.06.2024205Das Instrument PUQ CA95716A1021 WESTBRIDGE RE. EN. CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 06.06.2024 und ex Kapitalmassnahme am 07.06.2024 The instrument PUQ CA95716A1021 WESTBRIDGE RE....
► Artikel lesen
05.06.EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows1
05.06.Angle unveils plans to raise more than £10m1
05.06.Angle: Pharma firm's share price plunges after missing market forecasts2
16.05.Angle reports promising results from Parsortix study1
16.05.Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix139INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian cancer...
► Artikel lesen
03.05.Angle signs AstraZeneca deal to develop prostate cancer assay2
03.05.Angle shares up on assay development deal with AstraZenaca1
03.05.AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal1
03.05.Angle strikes supplier deal with AstraZeneca7
03.05.Angle PLC Announces New Commercial Agreement with Large Pharma216ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY),...
► Artikel lesen
24.04.SmallCap Risers and Fallers: Filtronic, Angle, Aptamer2
24.04.Angle inks deal with AstraZeneca3
24.04.Angle shares jump on supplier agreement with with AstraZeneca4
24.04.Angle agrees deal with Astrazeneca for tech to kill cancer cells4
24.04.Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca4
24.04.ANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection258LONDON (dpa-AFX) - ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response...
► Artikel lesen
24.04.Angle PLC Announces New Commercial Agreement with AstraZeneca190ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a...
► Artikel lesen
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1